ICTUImperial Clinical Trials Unit

Welcome to Imperial Clinical Trials Unit (ICTU)

This website is intended for people who are considering taking part in clinical trials and would like to find out more about what’s involved, why clinical trials are important and what the benefits of taking part in trials are. You can also find out about current clinical trials going on in ICTU and how to get involved.

Clinical Trials Search


CurrentAll Trials


Trial Details

Further Cardiovascular OUtcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Design and Objective

A double-blind, randomised, placebo-controlled, multicenter study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when a PCSK9 inhibitor is used in combination with optimal statin therapy in patients with clinically evident cardiovascular disease. The study has recruited 27,500 subjects from around the world (Europe, US, Canada, Australia, Asia, Latin America).

Key inclusion criteria

Male or female aged 40 to 85 years History of clinically evident cardiovascular disease (myocardial infarction, ischemic stroke, peripheral vascular disease) at high risk for a recurrent event Fasting LDL-C ≥ 70 mg/dL (1.8 mmol/L) or non-HDL-C ≥ 100 mg/dL (2.6 mmol/L) Fasting triglycerides ≤ 400 mg/dl (4.5 mmol/L)

Study Disclaimer Statement